Iovance Biotherapeutics

Iovance Biotherapeutics: Developing novel cancer immunotherapies based on tumor infiltrating lymphocytes (TIL) for the treatment of solid tumors. TIL therapy is a highly personalized approach in which patients receive a one-time treatment with their own expanded and rejuvenated T-cells to treat cancer. BLA expected in 1H22 following completion of pivotal study of Lifileucel/LN-144 for treatment of Melanoma. Other indications include Cervical, NSCL and HNSC Cancer
Sector/Industry:
Healthcare/Biotechnology
Characteristics:
Based in...
US - Pacific
Clinical Stage
Registration Stage
Disease Space
Immuno-Oncology, Immunotherapy
Finance
Pre-Revenues
Industry
Biotechnology
Listing
Public, USA
Market Cap
1B +
Therapeutic Modalities
Cell Therapy
Website:
Address:
999 Skyway Road
Suite 150
San Carlos, CA 94070
United States

Company Participants at Solebury Trout Virtual Management Access Event 2021

Maria Fardis, Ph.D.
Iovance Biotherapeutics, President/CEO
Dr. Maria Fardis serves as President, Chief Executive Officer and President at Iovance Biotherapeutics. She serves as Board Member at Kartos Therapeutics. She has extensive experience in drug development and novel cancer treatments. Prior to joining Lion Biotechnologies, Dr. Fardis was chief operating officer at Acerta Pharma working on the development of acalabrutinib until the company's acquisition by AstraZeneca. Before joining Acerta, Dr. Fardis held the position of chief of oncology operations and alliances at Pharmacyclics where she oversaw development of ibrutinib (IMBRUVICA®), abexinostat (HDAC inhibitor), and FVIIa inhibitor programs. She was a key contributor in the creation of a broad clinical program for ibrutinib, as well as NDA and MAA submissions. Previously, Dr. Fardis held a number of key scientific and management roles at Gilead Sciences. At Gilead, she was involved with multiple therapeutic areas including antivirals, oncology, and cardiovascular therapeutics and worked on the development and life cycle management of ambrisentan (Letairis®). She received her PhD in organic chemistry from UC Berkeley and holds an MBA from Golden Gate University.
Sara Pellegrino
Iovance Biotherapeutics, VP:IR & Public Relations
Dr. Fardis joined Iovance as President and Chief Executive Officer, and was appointed to the Company’s Board of Directors, in 2016. Prior to Iovance, Dr. Fardis served as the Chief Operating Officer of Acerta Pharma B.V., a clinical-stage biopharmaceutical company, where she worked on the development of Calquence® until the company’s acquisition by AstraZeneca. Previously, Dr. Fardis worked at Pharmacyclics, Inc., where she was a key contributor in the creation of a broad clinical program leading to global approvals for Imbruvica® in multiple hematologic malignancies, and where she served as Chief of Oncology Operations and Alliances. Prior to joining Pharmacyclics, Dr. Fardis held increasingly senior positions in Medicinal Chemistry and the project and portfolio management department at Gilead Sciences, Inc., where she was involved with multiple therapeutic areas including antivirals, oncology, and cardiovascular therapeutics and worked on the development and life cycle management of Letairis®. Dr. Fardis received her Ph.D. in Organic Chemistry from the University of California, Berkeley and her B.S., summa cum laude, in Chemistry from the University of Illinois, Urbana-Champaign. Dr. Fardis holds an M.B.A., with highest honors, from Golden Gate University.

Top 10 Holders of Iovance Biotherapeutics Inc

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
The Vanguard Group, Inc. 10.00 15,636,276 242.21 Funds 11/30/21
Vanguard Group, Inc. (Subfiler) 7.57 11,733,810 181.76 13F 9/30/21
ARK Investment Management LLC 7.51 11,649,837 180.46 13F 9/30/21
Perceptive Advisors LLC 7.41 11,489,772 177.98 13F 9/30/21
Wellington Management Co. LLP 5.74 8,899,530 137.85 13F 9/30/21
Avoro Capital Advisor LLC 5.48 8,500,000 131.67 13F 9/30/21
OrbiMed Advisors LLC 4.29 6,645,100 102.93 13F 9/30/21
Nikko Asset Management Americas, Inc. 4.12 6,380,803 98.84 13F 9/30/21
Sumitomo Mitsui Trust Holdings, Inc. 4.12 6,380,803 98.84 13F 9/30/21
Franklin Advisers, Inc. 4.02 6,238,692 96.64 13F 9/30/21
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2022 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.